HEALTHJul 21 · 12:40 UTCQUARTZCris Tolomia

Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal

Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion all-stock deal. The transaction grants Tempus control of Personalis' NeXT Personal cancer detection test.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Tempus AIorganizationPersonalisorganizationNeXT Personal cancer detection testtopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSMay 8 · 19:29 UTC
STAT+: Roche to buy PathAI for $750 million
BUSINESSJul 14 · 13:00 UTC
Zoetis acquires medical imaging company in latest push to build AI
BUSINESSJun 9 · 06:48 UTC
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
HEALTHJun 9 · 13:39 UTC
STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
BUSINESSJun 8 · 13:40 UTC
Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion